Description Developing a multiplex immunofluorescence assay for the in depth characterization of activatedT cells in tumor tissue samples.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description We describe the potential of accurate cellular phenotyping using the InSituPlex technology with fast whole-slide scanning using ZEISS Axioscan 7, an automated slide scanning system for fluorescence and transmitted light applications with modern cameras, a sophisticated focusing method and a powerful imaging software. The compounded effect of integrating these technologies can significantly improve the throughput of immuno-oncology research.

Description Understanding the complexities of the tumor micro-environment in detail can vastly improve the accuracy of immuno-oncology research and accelerate the discovery of potential immunotherapy targets. Multiplexed immunofluorescence (mIF) assays have emerged as a critical approach for identifying complex cellular phenotypes in the tumor micro-environment, powered by the value of the spatial correlation of such phenotypes in a tissue specimen. Although many methods for multiplexed IF exist, they are often costly and require time-consuming assay development and long imaging times. The Ultivue UltiMapper kits enable rapid, pre-optimized staining of multiple targets simultaneously in a single FFPE tissue section. This technology is ready-to-use with conventional automated staining workflows and commercially available automated imaging systems. Here, we demonstrate the potential of accurate cellular phenotyping using the InSituPlex technology with fast whole-slide scanning using ZEISS Axioscan.Z1 an automated slide scanning system for fluorescence and transmitted light applications with modern cameras, a sophisticated focusing method and a powerful imaging software. The compounded effect of integrating these technologies can significantly improve the throughput of immuno-oncology research. A 4-target immunostaining assay was performed on multiple FFPE tumor sections using UltiMapper reagents. Briefly, slides were stained with a cocktail of primary antibodies using a Leica Biosystems BOND RX autostainer. Post-staining, the slides were coverslipped and imaged on ZEISS Axioscan.Z1. The resulting images were analyzed using IndicaLabs HALO analysis software. In this poster, we report on an efficient and streamlined workflow for mIF staining, imaging, and analysis of tumor samples. After nuclear segmentation of the resulting images, T-cell and macrophage populations were subtyped and identified through spatial identification of relevant biomarkers. The combined workflow presented here allows a user to get 4-plex, whole slide immunofluorescence images of FFPE tumor tissues within 6 hours. The automated whole slide scanning capability of ZEISS Axioscan.Z1 also allows a user to image up to 100 slides with minimal external input. The combination of optimized, fast staining UltiMapper reagents with ZEISS Axioscan.Z1 automated whole-slide fluorescence scanner enables rapid, deep immunoprofiling within the spatial context of the tumor, empowering translational and immuno-oncology research.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Authors

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Marie Cumberbatch from TriStar Technology Group presented a poster of collaborative work between TriStar, Ultivue, and OracleBio at American Society of Clinical Oncology (ASCO) 2022 over the weekend. The work involved multiplex IF staining and analysis of multi-tumor tissue microarrays, with this poster focusing on the contribution of macrophages to the overall tumor PD-L1 microenvironment across different cancer types. Such target prevalence data can help guide options for successful immunotherapy strategies.

Description Profiling multiple cell types in tissue samples requires more markers than can be supported by conventional approaches to immunohistochemistry. InSituPlex® multipleximmunofluorescence (mIF) technology enables biomarker multiplexing int issue samples with an automated workflow to support discovery of immunecell signatures in the tumor immunemicroenvironment (TiME).Here we have designed and tested an 8- plex immuno phenotyping panel using the InSituPlex® approach to detect and classify T cells, macrophages, and tumor cell in non- small cell lung cancer (NSCLC) and colorectal cancer (CRC) FFPE tissue.